C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in C4 Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 107
- +24 vs. Q1 2021
- Shares held
- 31.9M
- +6.85M (+27.3%) vs. Q1 2021
- Total value
- $1.21B
- +$282.7M (+30.5%) vs. Q1 2021
- New holders
- 36
- 43 more added
- Sold out
- 12
- 14 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CCCC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 147 | $547.6M |
| Q1 2026 | 123 | $221.3M |
| Q4 2025 | 101 | $152.5M |
| Q3 2025 | 97 | $116.6M |
| Q2 2025 | 102 | $78.2M |
| Q1 2025 | 115 | $102.6M |
| Q4 2024 | 113 | $231.8M |
| Q3 2024 | 118 | $365.9M |
| Q2 2024 | 115 | $281.3M |
| Q1 2024 | 106 | $475.6M |
| Q4 2023 | 92 | $265.6M |
| Q3 2023 | 84 | $64.5M |
| Q2 2023 | 100 | $94.1M |
| Q1 2023 | 121 | $117.5M |
| Q4 2022 | 117 | $231.4M |
| Q3 2022 | 114 | $345.9M |
| Q2 2022 | 113 | $297.2M |
| Q1 2022 | 125 | $904.8M |
| Q4 2021 | 119 | $1.15B |
| Q3 2021 | 113 | $1.54B |
| Q2 2021 | 107 | $1.21B |
| Q1 2021 | 83 | $926.8M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding C4 Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| O'Shaughnessy Asset Management, LLC | 1,037 | $39.0K | 0.00% | 00.0% | Unchanged |
| Nisa Investment Advisors, LLC | 690 | $26.0K | 0.00% | +690 | New |
| Russell Investments Group, Ltd. | 562 | $21.0K | 0.00% | +562 | New |
| Piscataqua Savings Bank | 401 | $15.0K | 0.01% | 00.0% | Unchanged |
| Endurance Wealth Management, Inc. | 350 | $15.0K | 0.00% | 00.0% | Unchanged |
| TCI Wealth Advisors, Inc. | 72 | $3.00K | 0.00% | +72 | New |
| Wells Fargo & Company | 35 | $0 | 0.00% | −5,244−99.3% | Reduced |
| Darwin Global Management, Ltd. | 0 | $0 | 0.00% | −140,034−100.0% | Sold out |
| Federated Hermes, Inc. | 0 | $0 | 0.00% | −38,975−100.0% | Sold out |
| Bank Julius Baer & Co. Ltd, Zurich | 0 | $0 | 0.00% | −33,905−100.0% | Sold out |
| Zimmer Partners, LP | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Affinity Asset Advisors, LLC | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| California Public Employees Retirement System | 0 | $0 | 0.00% | −19,490−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −12,026−100.0% | Sold out |
| Athanor Capital, LP | 0 | $0 | 0.00% | −10,132−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −5,699−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −1,096−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −291−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −84−100.0% | Sold out |